Ibandronate
- Atc Codes:M05BA06
- CAS Codes:138926-19-9
- PHARMGKB ID:138926-19-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Bondronat, Bonviva; Belgium: Bondronat, Bonviva; Bulgaria: Bonviva; Czech Republic: Bondenza, Bondronat, Bonviva; Denmark: Bondronat; Estonia: Bondenza, Bondronat, Bonviva; Finland: Bondronat, Bonviva; France: Bondronat, Bonviva; Germany: Bondenza, Bondronat, Bonviva; Greece: Destara; Hungary: Bondenza, Bondronat, Bonviva; Ireland: Bondenza, Bondronat, Bonviva, Ibandronic Acid; Italy: Bondronat, Bonviva; Latvia: Bondenza, Bondronat, Bonviva; Luxembourg: Bondenza, Bondronat, Bonviva; Malta: Ibandronic Acid; Netherlands: Bondenza, Bondronat, Bonviva, Destara; Poland: Bondenza, Bondronat, Bonviva; Portugal: Acido Ibandrónico, Bondenza, Bondronat, Bonviva; Spain: Bondenza, Bondronat, Bonviva; Sweden: Bondenza, Bondronat, Bonviva; UK: Bondronat, Bonviva.
North America
USA: Boniva.
Latin America
Argentina: Adromux, Bandrobon, Bantuc, Bonviva, Brexell Plus, Deltrox, Elasterin, Femorel, Ibanleg, Idena, Modifical-Beta, Silidral Uno; Brazil: Bonviva; Mexico: Bonviva.
Drug combinations
Chemistry
Ibandronate Sodium: C~9~H~22~NNaO~7~P~2~ H~2~O. Mw: 359.23. Sodium trihydrogen [1-hydroxy-3-(methylpentylamino)propylidene]diphosphonate, monohydrate. CAS-138926-19-9 (1997).
Pharmacologic Category
Bone Resorption Inhibitors; Bisphosphonate Derivative. (ATC-Code: M05BA06).
Mechanism of action
Incorporates into bone and selectively inhibits osteoclast-mediated bone resorption. Reduces biochemical markers of bone resorption in postmenopausal osteoporosis. Maintains or increases bone mineral density and increases bone mass in postmenopausal women.
Therapeutic use
Treatment and prevention of osteoporosis in postmenopausal women.
Pregnancy and lactiation implications
Safety and efficacy not established in pregnant women. Bisphosphonates are incorporated into bone matrix and gradually released over time. There may be risk of fetal harm when pregnancy follows completion of therapy.
Unlabeled use
Hypercalcemia of malignancy. Corticosteroid-induced osteoporosis. Paget’s disease. Reduction of bone pain and skeletal complications from metastatic bone disease.
Contraindications
Hypersensitivity to ibandronate, other bisphosphonates, or any component of the formulation. Hypocalcemia. Oral tablets also contraindicated in patients unable to stand or sit upright for at least 60 minutes.
Warnings and precautions
Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain reported during bisphosphonate treatment (avoid use in history of these symptoms in association with bisphosphonate therapy). Gastrointestinal mucosa irritation possible (use with caution in duodenitis, dysphagia, esophageal disease, gastritis, or ulcers). Osteonecrosis of jaw might occur (observed mostly in cancer patients, but also in postmenopausal osteoporosis and other diagnoses). Invasive dental procedures should be avoided during treatment. Before therapy initiation hypocalcemia must be corrected. Use not recommended with severe renal impairment (CrCl <30 mL/minute or serum creatinine >2.3 mg/dL). Intravenous bisphosphonates may cause transient decreases in serum calcium and also associated with renal toxicity.